Reply: Complicated hereditary spastic paraplegia due to ATP13A2 mutations: what's in a name?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

1. Identification of a novel mutation inNeurology. Genetics · 2020
   Article
2. FAHN/SPG35: a narrow phenotypic spectrum across disease classifications.Brain : a journal of neurology · 2019
   Article

Corrections and comments

• Comment on
  Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).2017
• Comment on
  Complicated hereditary spastic paraplegia due to ATP13A2 mutations: what's in a name?2017

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as